Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Post Anti-PD-1 Melanoma: early-phase trial registry
A small indexed set (1 trial) with no open enrollment listed right now.
Corpus placement: #11,370 of 28,707 conditions by registered trial count.
1 US clinical trials · none currently recruiting · #11,370 of 28,707 conditions by registered trial count
Post Anti-PD-1 Melanoma: 1 US clinical trial tracked, none currently recruiting.
Post Anti-PD-1 Melanoma is the subject of 1 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Ascendis Pharma Oncology Division A/S, running 1 of these trials.
Enrollment posture brief
Registry condition post-anti-pd-1-melanoma
OPEN 0 | RECR 0% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Post Anti-PD-1 Melanoma has no open enrollment in this registry pull (1 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Post Anti-PD-1 Melanoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Post Anti-PD-1 Melanoma is recruiting below its size-band peers.
0 of 1 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
1 total, page 1 of 1
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Post Anti-PD-1 Melanoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Post Anti-PD-1 Melanoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Post Anti-PD-1 Melanoma page
1 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Post Anti-PD-1 Melanoma trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Ascendis Pharma Oncology Division A/S sponsors the most Post Anti-PD-1 Melanoma trials on record, review their full trial history before evaluating a specific study. See Ascendis Pharma Oncology Division A/S's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Post Anti-PD-1 Melanoma condition card totals 1 registered trials; most-linked intervention TransCon TLR7/8 Agonist; top US site state Virginia. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.